title,url,time_published,summary,ticker,relevance_score,ticker_sentiment_score,ticker_sentiment_label
BIO-TECHNE'S ADVANCED CELL DIAGNOSTICS  ( ACD )  SETS NEW STANDARD IN SPATIAL BIOLOGY WITH PROTEASE-FREE RNASCOPE MULTIOMICS,https://www.prnewswire.com/news-releases/bio-technes-advanced-cell-diagnostics-acd-sets-new-standard-in-spatial-biology-with-protease-free-rnascope-multiomics-302046066.html,2024-01-29 12:00:00,BIO-TECHNE'S ADVANCED CELL DIAGNOSTICS ( ACD ) SETS NEW STANDARD IN SPATIAL BIOLOGY WITH ... PR ...,TECH,0.558244,0.343139,Somewhat-Bullish
Fetal Bovine Serum Market Projected to Reach USD 12.9 Bn at 16.5% CAGR from 2023-2033 | Marketresearch.biz Study,https://www.benzinga.com/pressreleases/24/01/g36819322/fetal-bovine-serum-market-projected-to-reach-usd-12-9-bn-at-16-5-cagr-from-2023-2033-marketresearc,2024-01-29 07:12:09,"New York, Jan. 29, 2024 ( GLOBE NEWSWIRE ) -- The fetal bovine serum market was valued at USD 2.9 billion in 2023 with significant growth and is projected to reach USD 12.9 billion by 2033 with an outstanding CAGR of 16.5%.",TECH,0.02665,0.084229,Neutral
CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market to grow by USD 2.23 billion between 2023 and ... - PR Newswire,https://www.prnewswire.com/news-releases/ctla4-cytotoxic-t-lymphocyte-associated-protein-4-inhibitors-market-to-grow-by-usd-2-23-billion-between-2023-and-2028--growth-driven-by-high-target-affinity-and-specificity-of-ctla4-inhibitors---technavio-302044103.html,2024-01-26 01:15:00,CTLA4 ( Cytotoxic T-Lymphocyte-Associated Protein 4 ) Inhibitors Market to grow by USD 2.23 billion between 2023 and ... PR ...,TECH,0.042953,-0.040851,Neutral
Liquid Biopsy in Cancer Diagnostics Global Market is Likely to Increase at a Massive Growth Rate of ~17% by 2028 | DelveInsight,https://www.prnewswire.com/news-releases/liquid-biopsy-in-cancer-diagnostics-global-market-is-likely-to-increase-at-a-massive-growth-rate-of-17-by-2028--delveinsight-302039144.html,2024-01-19 22:01:00,Liquid Biopsy in Cancer Diagnostics Global Market is Likely to Increase at a Massive Growth Rate of ~17% by 2028 ... PR ...,TECH,0.042271,0.018936,Neutral
Stem Cell Assays Market Size & Share to Surpass USD 8.5 billion by 2033 | Analysis by Transparency Market Research,https://www.benzinga.com/pressreleases/24/01/g36678654/stem-cell-assays-market-size-share-to-surpass-usd-8-5-billion-by-2033-analysis-by-transparency-mar,2024-01-18 14:30:00,"Wilmington, Delaware, United States, Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global stem cell assays market is estimated to flourish at a CAGR of 16.5% from 2023 to 2033.",TECH,0.035241,0.0,Neutral
"Biomarkers Market size to grow by USD 56.26 billion from 2022 to 2027| Abbott Laboratories, Abcam plc, Agilent ... - PR Newswire",https://www.prnewswire.com/news-releases/biomarkers-market-size-to-grow-by-usd-56-26-billion-from-2022-to-2027-abbott-laboratories-abcam-plc-agilent-technologies-inc-and-more-among-the-key-companies-in-the-market---technavio-302004841.html,2023-12-05 01:30:00,"Biomarkers Market size to grow by USD 56.26 billion from 2022 to 2027| Abbott Laboratories, Abcam plc, Agilent ... PR ...",TECH,0.07913,-0.019424,Neutral
"Cell Surface Markers Market size to grow by USD 14.06 billion from 2023-2028| Abbott Laboratories, Abcam plc ... - PR Newswire",https://www.prnewswire.com/news-releases/cell-surface-markers-market-size-to-grow-by-usd-14-06-billion-from-2023-2028-abbott-laboratories-abcam-plc-agilent-technologies-inc-and-more-among-the-key-companies-in-the-market---technavio-301996069.html,2023-11-23 01:30:00,"Cell Surface Markers Market size to grow by USD 14.06 billion from 2023-2028| Abbott Laboratories, Abcam plc ... PR ...",TECH,0.064797,0.0,Neutral
The Difficult-To-Express Proteins Market Is Expected To Grow At A Rate Of More Than 11% Through 2023-2027 As Per The Business Research Company's Difficult-To-Express Proteins Global Market Report 2023,https://www.benzinga.com/pressreleases/23/11/g35755379/the-difficult-to-express-proteins-market-is-expected-to-grow-at-a-rate-of-more-than-11-through-202,2023-11-13 16:30:00,"LONDON, Nov. 13, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Difficult-To-Express Proteins Global Market Report 2023, the global difficult-to-express proteins market is set to experience significant growth, with a projected increase from $3.65 billion in 2022 to $4.11 ...",TECH,0.065685,0.159347,Somewhat-Bullish
Cell and Gene Therapy Manufacturing Market to Achieve a Valuation of USD 8.8 billion by 2031| Analysis by Transparency Market Research,https://www.benzinga.com/pressreleases/23/11/g35699021/cell-and-gene-therapy-manufacturing-market-to-achieve-a-valuation-of-usd-8-8-billion-by-2031-analy,2023-11-09 13:30:00,"Wilmington, Delaware, United States, Nov. 09, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global cell and gene therapy manufacturing market is projected to flourish at a CAGR of 25.2% from 2023 to 2031.",TECH,0.039811,0.0,Neutral
Bio-Techne  ( NASDAQ:TECH )  Stock Rating Lowered by StockNews.com,https://www.defenseworld.net/2023/11/04/bio-techne-nasdaqtech-stock-rating-lowered-by-stocknews-com.html,2023-11-04 07:20:49,Bio-Techne ( NASDAQ:TECH ) Stock Rating Lowered by StockNews ... Defense World ...,TECH,0.853716,0.452718,Bullish
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2024 RESULTS,https://www.prnewswire.com/news-releases/bio-techne-releases-first-quarter-fiscal-2024-results-301972276.html,2023-10-31 10:30:00,"MINNEAPOLIS, Oct. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation ( NASDAQ: TECH ) today reported its financial results for the first quarter ended September 30, 2023. • First quarter organic revenue increased by 2% ( 3% reported ) to . • GAAP earnings per share1 ) ( EPS ) was versus one year ...",TECH,0.197559,0.232825,Somewhat-Bullish
Bio-Techne  ( NASDAQ:TECH )  Rating Increased to Buy at StockNews.com,https://www.defenseworld.net/2023/10/29/bio-techne-nasdaqtech-rating-increased-to-buy-at-stocknews-com.html,2023-10-29 05:34:43,Bio-Techne ( NASDAQ:TECH ) Rating Increased to Buy at StockNews ... Defense World ...,TECH,0.897925,0.454911,Bullish
Bio-Techne  ( NASDAQ:TECH )  Cut to Hold at StockNews.com,https://www.defenseworld.net/2023/10/21/bio-techne-nasdaqtech-cut-to-hold-at-stocknews-com.html,2023-10-21 06:00:46,"Bio-Techne ( NASDAQ:TECH - Get Free Report ) was downgraded by investment analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a note issued to investors on Thursday. Other equities analysts have also issued research reports about the stock.",TECH,0.877585,0.454819,Bullish
BIO-TECHNE APPOINTS KIM KELDERMAN AS CHIEF EXECUTIVE OFFICER - PR Newswire,https://www.prnewswire.com/news-releases/bio-techne-appoints-kim-kelderman-as-chief-executive-officer-301961575.html,2023-10-19 11:00:00,BIO-TECHNE APPOINTS KIM KELDERMAN AS CHIEF EXECUTIVE OFFICER PR ...,TECH,0.545243,0.439426,Bullish
Immunohistochemistry (IHC) Market size to grow by USD 1.06 billion from 2022-2027 | Agilent Technologies Inc ... - PR Newswire,https://www.prnewswire.com/news-releases/immunohistochemistry-ihc-market-size-to-grow-by-usd-1-06-billion-from-2022-2027--agilent-technologies-inc-miltenyi-biotec-bv-and-co-kg-perkinelmer-inc-are-some-of-the-major-companies--technavio-301956382.html,2023-10-16 21:01:00,Immunohistochemistry ( IHC ) Market size to grow by USD 1.06 billion from 2022-2027 | Agilent Technologies Inc ... PR ...,TECH,0.062761,0.062012,Neutral
Bio-Techne Upgraded to Buy Rating by StockNews.com,https://www.claytoncountyregister.com/news2/bio-techne-nasdaqtech-lifted-to-buy-at-stocknews-com/580601/,2023-10-15 08:00:11,"Bio-Techne, a life science company that develops and sells reagents, instruments, and services for the research and clinical diagnostic markets, has been upgraded to a buy rating by StockNews.com. The move comes after other reports issued buy ratings and positive target prices on the stock.",TECH,0.580018,0.297037,Somewhat-Bullish
Bio-Techne  ( NASDAQ:TECH )  Upgraded by StockNews.com to Buy,https://www.defenseworld.net/2023/10/12/bio-techne-nasdaqtech-upgraded-by-stocknews-com-to-buy.html,2023-10-12 08:43:01,StockNews.com upgraded shares of Bio-Techne ( NASDAQ:TECH - Free Report ) from a hold rating to a buy rating in a report issued on Wednesday. Several other equities research analysts also recently weighed in on the company. Robert W.,TECH,0.734464,0.426116,Bullish
3Q23 Earnings: Where Street Earnings Are Too High & Who Should Miss,https://www.forbes.com/sites/greatspeculations/2023/10/11/3q23-earnings-where-street-earnings-are-too-high--who-should-miss/,2023-10-11 13:26:01,Insights on which companies are most likely to miss 3Q23 earnings based on our proprietary Core Earnings research.,TECH,0.203386,-0.069925,Neutral
3 Healthcare Stocks to Keep an Eye On,https://www.fool.com/investing/2023/10/03/3-healthcare-stocks-to-keep-an-eye-on/,2023-10-03 13:45:00,These three lesser-known healthcare companies have strong growth potential.,TECH,0.236972,0.222992,Somewhat-Bullish
StockNews.com Downgrades Bio-Techne  ( NASDAQ:TECH )  to Hold,https://www.defenseworld.net/2023/10/01/stocknews-com-downgrades-bio-techne-nasdaqtech-to-hold.html,2023-10-01 06:26:45,"Bio-Techne ( NASDAQ:TECH - Get Free Report ) was downgraded by analysts at StockNews.com from a ""buy"" rating to a ""hold"" rating in a research report issued to clients and investors on Friday. TECH has been the subject of several other research reports.",TECH,0.914215,0.470046,Bullish
"Bio-Techne Downgraded to ""Hold"" Rating",https://www.claytoncountyregister.com/news2/bio-techne-nasdaqtech-lowered-to-hold-at-stocknews-com/518941/,2023-10-01 01:58:07,"Bio-Techne ( NASDAQ: TECH ) has been downgraded from a ""buy"" rating to a ""hold"" rating by StockNews.com. Other equities research analysts have also issued research reports about the company, including Royal Bank of Canada, Benchmark, Stephens, and William Blair.",TECH,0.774534,0.055502,Neutral
BIO-TECHNE ISSUES 2023 CORPORATE SUSTAINABILITY REPORT,https://www.prnewswire.com/news-releases/bio-techne-issues-2023-corporate-sustainability-report-301936411.html,2023-09-25 11:00:00,"MINNEAPOLIS, Sept. 25, 2023 /PRNewswire/ -- Bio-Techne Corporation ( NASDAQ: TECH ) today issued its 2023 Corporate Sustainability Report ( CSR ) , detailing the continued progress advancing its Environmental, Social and Governance ( ESG ) initiatives.",TECH,0.829759,0.689619,Bullish
6 Healthcare Stocks Analysts Still Like,https://www.barrons.com/articles/healthcare-stocks-analysts-like-8b0f4dd2,2023-09-20 07:00:00,"This has been an epically bad year for the healthcare sector, but there are still a few stocks out there that Wall Street analysts like. Some of them are even more beaten down than the rest of the industry. The S&P 500 Health Care sector index is down 3% this year, vastly behind the S&P 500, ...",TECH,0.240489,0.079998,Neutral
Bio-Techne  ( NASDAQ:TECH )  Upgraded to Buy at StockNews.com,https://www.defenseworld.net/2023/09/05/bio-techne-nasdaqtech-upgraded-to-buy-at-stocknews-com.html,2023-09-05 06:58:47,StockNews.com upgraded shares of Bio-Techne ( NASDAQ:TECH - Free Report ) from a hold rating to a buy rating in a research report report published on Monday morning. TECH has been the subject of a number of other reports.,TECH,0.781478,0.392994,Bullish
Life Science Firm Bio-Techne's Success Formula: Astute Acquisitions Offering Transformation - Bio-Techne  ( NASDAQ:TECH ) ,https://www.benzinga.com/news/23/08/34074599/life-science-firm-bio-technes-success-formula-astute-acquisitions-offering-transformation,2023-08-28 20:09:51,"William Blair has initiated coverage on coverage of Bio-Techne Corp TECH with an Outperform rating. Bio-Techne is positioned in high-growth and attractive end-markets, notably cell and gene therapy ( C> ) , spatial biology, and liquid biopsy, representing a total addressable market ( TAM ) of ...",TECH,0.605937,0.378658,Bullish
"Cell and Gene Therapy Manufacturing Quality Control  ( QC )  Market to Reach USD 2.8 billion by 2031, Expanding at a CAGR of 24.6 % Says, Transparency Market Research",https://www.benzinga.com/pressreleases/23/08/g34062747/cell-and-gene-therapy-manufacturing-quality-control-qc-market-to-reach-usd-2-8-billion-by-2031-exp,2023-08-28 08:01:00,"Wilmington, Delaware, United States, Aug. 28, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global cell and gene therapy manufacturing quality control ( QC ) market is projected to flourish at a CAGR of 24.6% from 2023 to 2031.",TECH,0.039289,0.0,Neutral
"Bio-Techne  ( NASDAQ:TECH )  Upgraded by StockNews.com to ""Buy""",https://www.defenseworld.net/2023/08/25/bio-techne-nasdaqtech-upgraded-by-stocknews-com-to-buy.html,2023-08-25 05:46:42,"Bio-Techne ( NASDAQ:TECH - Get Free Report ) was upgraded by investment analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research note issued to investors on Friday. A number of other equities analysts have also commented on the stock. Robert W.",TECH,0.831224,0.4793,Bullish
New Strong Sell Stocks for August 22nd,https://www.zacks.com/stock/news/2138928/new-strong-sell-stocks-for-august-22nd,2023-08-22 08:41:00,"AVTR, BHLB and TECH have been added to the Zacks Rank #5 (Strong Sell) List on August 22, 2023.",TECH,0.601928,-0.222014,Somewhat-Bearish
Biopreservation Market size to grow by USD 2.40 billion from 2022 to 2027 | The growing demand for personalized ... - PR Newswire,https://www.prnewswire.com/news-releases/biopreservation-market-size-to-grow-by-usd-2-40-billion-from-2022-to-2027--the-growing-demand-for-personalized-medicine-drives-the-market---technavio-301904111.html,2023-08-19 03:30:00,Biopreservation Market size to grow by USD 2.40 billion from 2022 to 2027 | The growing demand for personalized ... PR ...,TECH,0.100308,-0.055166,Neutral
BIO-TECHNE ENDS COLLABORATION PROGRAM WITH AKOYA TO AUTOMATE RNASCOPE ON THE PHENOCYCLER FUSION,https://www.prnewswire.com/news-releases/bio-techne-ends-collaboration-program-with-akoya-to-automate-rnascope-on-the-phenocycler-fusion-301899458.html,2023-08-14 11:00:00,BIO-TECHNE ENDS COLLABORATION PROGRAM WITH AKOYA TO AUTOMATE RNASCOPE ON THE ... PR ...,TECH,0.898236,0.459988,Bullish
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2023 RESULTS,https://www.prnewswire.com/news-releases/bio-techne-releases-fourth-quarter-fiscal-2023-results-301895161.html,2023-08-08 10:30:00,"MINNEAPOLIS, Aug. 8, 2023 /PRNewswire/ -- Bio-Techne Corporation ( NASDAQ: TECH ) today reported its financial results for the fourth quarter ended June 30, 2023. • Fourth quarter organic revenue increased by 5% ( 5% reported ) to .",TECH,0.179232,0.188852,Somewhat-Bullish
"DNA and Gene Cloning Services Market likely to surpass USD 9 billion, expected to expand at a 13.7% CAGR from 2022 to 2031: TMR Report",https://www.benzinga.com/pressreleases/23/08/g33551152/dna-and-gene-cloning-services-market-likely-to-surpass-usd-9-billion-expected-to-expand-at-a-13-7-,2023-08-03 14:30:00,"Wilmington, Delaware, United States, Aug. 03, 2023 ( GLOBE NEWSWIRE ) -- The global market for DNA and gene cloning services was estimated to have garnered a global market valuation around US$ 2.5 billion in 2022.",TECH,0.039745,0.040407,Neutral
BIO-TECHNE COMPLETES LUNAPHORE ACQUISITION,https://www.prnewswire.com/news-releases/bio-techne-completes-lunaphore-acquisition-301872402.html,2023-07-10 11:00:00,"MINNEAPOLIS, July 10, 2023 /PRNewswire/ -- Bio-Techne Corporation ( NASDAQ:TECH ) today announced it has completed the acquisition of Lunaphore Technologies SA, a leading developer of fully automated spatial biology solutions.",TECH,0.172713,0.108308,Neutral
Prostate Cancer Global Market to Witness Upsurge in Growth at a CAGR of ~5% by 2028 | DelveInsight,https://www.prnewswire.com/news-releases/prostate-cancer-global-market-to-witness-upsurge-in-growth-at-a-cagr-of-5-by-2028--delveinsight-301869890.html,2023-07-05 21:01:00,"The prostate cancer market is anticipated to propel owing to the increasing incidence of prostate cancer around the world, the rising number of risk factors for prostate cancer, growing technological advancements in prostate cancer diagnostics, government, and non-government awareness ...",TECH,0.027195,-0.051647,Neutral
Exosome Diagnostics and Therapeutics Market size to grow by USD 483.18 million from 2022 to 2027|Increasing research on exosomes for new therapeutics driving the market - Technavio,https://www.prnewswire.com/news-releases/exosome-diagnostics-and-therapeutics-market-size-to-grow-by-usd-483-18-million-from-2022-to-2027increasing-research-on-exosomes-for-new-therapeutics-driving-the-market---technavio-301867242.html,2023-06-30 05:15:00,Exosome Diagnostics and Therapeutics Market size to grow by USD 483.18 million from 2022 to 2027|Increasing ... PR ...,TECH,0.061394,0.033013,Neutral
"Fetal Bovine Serum Market to Grow at a CAGR of 6.4% from 2021 to 2031, reaching US$ 1.6 Billion: As per TMR Study",https://www.benzinga.com/pressreleases/23/06/g33054658/fetal-bovine-serum-market-to-grow-at-a-cagr-of-6-4-from-2021-to-2031-reaching-us-1-6-billion-as-pe,2023-06-29 09:30:00,"Wilmington, Delaware, United States, June 29, 2023 ( GLOBE NEWSWIRE ) -- The global fetal bovine serum market stood at US$ 842.7 billion in 2020, and the global market is projected to reach US$ 1.6 billion by 2031. The global industry is anticipated to record a CAGR of 6.4% between 2021 and 2031.",TECH,0.03704,-0.073693,Neutral
Cell culture market size to increase by USD 17.74 billion from 2022 to 2027; North America to contribute 39% of market growth - Technavio,https://www.prnewswire.com/news-releases/cell-culture-market-size-to-increase-by-usd-17-74-billion-from-2022-to-2027-north-america-to-contribute-39-of-market-growth---technavio-301858375.html,2023-06-23 14:15:00,Cell culture market size to increase by USD 17.74 billion from 2022 to 2027. North America to contribute 39% of market ... PR ...,TECH,0.025679,0.0,Neutral
"Global Serum Market Forecast 2023-2032 - Market Size, Drivers, Trends, And Competitors As Per The Business Research Company's Serum Global Market Report 2023",https://www.benzinga.com/pressreleases/23/06/g32969856/global-serum-market-forecast-2023-2032-market-size-drivers-trends-and-competitors-as-per-the-busin,2023-06-22 15:30:00,"LONDON, June 22, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Serum Global Market Report 2023, the market will grow from$1.1 billion in 2022 to $1.2 billion in 2023, at a compound annual growth rate ( CAGR ) of more than 10%.",TECH,0.056407,-0.055915,Neutral
Bio-Techne's Acquisition of Lunaphore Expands Its Spatial Biology Offerings - Bio-Techne  ( NASDAQ:TECH ) ,https://www.benzinga.com/news/large-cap/23/06/32967937/bio-technes-acquisition-of-lunaphore-expands-its-spatial-biology-offerings,2023-06-22 14:57:54,"Bio-Techne Corporation TECH has agreed to acquire Lunaphore Inc with undisclosed deal terms. Lunaphore, founded in 2014 and based in Tolochenaz, Switzerland, develops fully automated spatial biology solutions using precision microfluidic technology.",TECH,0.751437,0.351896,Bullish
BIO-TECHNE TO ACQUIRE LUNAPHORE,https://www.prnewswire.com/news-releases/bio-techne-to-acquire-lunaphore-301857071.html,2023-06-22 12:00:00,"MINNEAPOLIS and TOLOCHENAZ, Switzerland, June 22, 2023 /PRNewswire/ -- Bio-Techne Corporation ( NASDAQ:TECH ) , a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to ...",TECH,0.245752,0.338713,Somewhat-Bullish
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation - Abcam  ( NASDAQ:ABCM ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/06/32930681/abcam-downgrade-analyst-trims-expectations-amid-activist-investor-engagement-and-po,2023-06-20 18:37:22,"RBC Capital Markets has downgraded Abcam PLC ABCM from Outperform to Sector Perform with a price target of $22, down from $23. The analyst writes that it has always liked Abcam's fundamentals but sees activist investor engagement and anticipation of a potential bid as likely to drive material ...",TECH,0.31282,0.410289,Bullish
"Epigenetics Market size to grow by USD 1,148.2 million from 2022-2027 with 40% of the market growth originate from North America - Technavio",https://www.prnewswire.com/news-releases/epigenetics-market-size-to-grow-by-usd-1-148-2-million-from-2022-2027-with-40-of-the-market-growth-originate-from-north-america---technavio-301852330.html,2023-06-16 14:15:00,"Epigenetics Market size to grow by USD 1,148.2 million from 2022-2027 with 40% of the market growth originate from ... PR ...",TECH,0.033098,0.02861,Neutral
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023,https://www.globenewswire.com/news-release/2023/06/09/2685445/0/en/Renalytix-Reports-Financial-Results-for-Third-Quarter-of-Fiscal-Year-2023.html,2023-06-09 11:00:00,"LONDON and SALT LAKE CITY, June 09, 2023 ( GLOBE NEWSWIRE ) -- Renalytix plc ( NASDAQ: RNLX ) ( LSE: RENX ) , an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based ...",TECH,0.002369,0.028923,Neutral
This Favorable Sign Appears On Bio-Techne's Chart - Bio-Techne  ( NASDAQ:TECH ) ,https://www.benzinga.com/markets/23/05/32649313/this-favorable-sign-appears-on-bio-technes-chart,2023-05-31 14:48:33,"If history is any guide, there may be good fortune ahead for shares of Bio-Techne TECH. A so-called ""golden cross"" has formed on its chart and, not surprisingly, this could be bullish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions.",TECH,0.459624,0.563976,Bullish
StockNews.com Initiates Coverage on Bio-Techne  ( NASDAQ:TECH ) ,https://www.defenseworld.net/2023/05/18/stocknews-com-initiates-coverage-on-bio-techne-nasdaqtech.html,2023-05-18 07:54:43,"Analysts at StockNews.com initiated coverage on shares of Bio-Techne ( NASDAQ:TECH - Get Rating ) in a research note issued to investors on Thursday. The firm set a ""hold"" rating on the biotechnology company's stock. Other equities research analysts have also recently issued research reports ...",TECH,0.888655,0.473727,Bullish
Polyclonal Antibodies Market is to reach USD 1.44 Billion by 2029 at a growth rate of 5.2 percent over the forecast period,https://www.benzinga.com/pressreleases/23/05/g32418565/polyclonal-antibodies-market-is-to-reach-usd-1-44-billion-by-2029-at-a-growth-rate-of-5-2-percent-,2023-05-16 11:44:53,"Pune, May 16, 2023 ( GLOBE NEWSWIRE ) -- Maximize Market Research, a global Healthcare market research firm has published competitive intelligence and market research report on the ""Polyclonal Antibodies Market"". The Polyclonal Antibodies Market size was valued at USD 1.44 Billion in 2022.",TECH,0.03453,0.405841,Bullish
"This Analyst With 83% Accuracy Rate Sees Around 11% Upside In Texas Roadhouse - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts - Enovis  ( NYSE:ENOV ) , FIGS  ( NYSE:FIGS ) ",https://www.benzinga.com/news/23/05/32261476/this-analyst-with-83-accuracy-rate-sees-around-11-upside-in-texas-roadhouse-here-are-5-stock-picks-f,2023-05-08 11:47:35,"U.S stocks closed higher on Friday, with the Dow Jones jumping more than 500 points during the session. Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements.",TECH,0.235062,0.237484,Somewhat-Bullish
Recombinant proteins market is projected to grow at a CAGR of 11.14% by 2033: Visiongain Reports Ltd,https://www.benzinga.com/pressreleases/23/05/g32242599/recombinant-proteins-market-is-projected-to-grow-at-a-cagr-of-11-14-by-2033-visiongain-reports-ltd,2023-05-05 15:43:06,"Visiongain has published a new report: Recombinant Proteins Market: Forecasts by Products & Services ( Cytokines & Growth Factors ( Interferons ( IFNs ) , Interleukins ( ILS ) , Others ) , Antibodies, Enzymes ( Kinases Enzymes, Metabolic Enzymes, Others ) , Recombinant Regulatory Protein, ...",TECH,0.029292,0.058959,Neutral
"Exosome Technologies Market Value to Reach USD 343.5 Mn by 2031, rising at a CAGR of 24.8%: TMR Study",https://www.benzinga.com/pressreleases/23/05/g32237327/exosome-technologies-market-value-to-reach-usd-343-5-mn-by-2031-rising-at-a-cagr-of-24-8-tmr-study,2023-05-05 12:30:00,"Wilmington, Delaware, United States, May 05, 2023 ( GLOBE NEWSWIRE ) -- The global exosome technologies market was valued at USD 47.3 Mn in 2022 and is projected to exceed USD 343.5 Mn by 2031.",TECH,0.038969,0.156727,Somewhat-Bullish
The Circulating Tumor Cells Market Size Is Expected To Reach $16.7 Billion By 2027 As Per The Business Research Company's Circulating Tumor Cells Global Market Report 2023,https://www.benzinga.com/pressreleases/23/05/g32217711/the-circulating-tumor-cells-market-size-is-expected-to-reach-16-7-billion-by-2027-as-per-the-busin,2023-05-04 15:30:00,"LONDON, May 04, 2023 ( GLOBE NEWSWIRE ) -- The Business Research Company's research on the circulating tumor cells market forecasts the global market size for circulating tumor cells to increase from $9.5 billion in 2022 to $10.7 billion in 2023, with a compound annual growth rate ( CAGR ) of ...",TECH,0.061159,0.137293,Neutral
Avid Bioservices Joins Elite Club Of Stocks With RS Ratings Over 90,https://www.investors.com/research/avid-bioservices-joins-elite-club-of-stocks-with-rs-ratings-over-90/,2023-04-24 19:41:00,"On Monday, Avid Bioservices ( CDMO ) hit an important technical milestone, seeing its Relative Strength ( RS ) Rating jump into the 90-plus percentile with an improvement to 91, up from 87 the day before. When looking for the best stocks to buy and watch, one factor to watch closely is ...",TECH,0.233556,0.101225,Neutral
Avid Bioservices Joins Elite Club Of Stocks With RS Ratings Over 90,https://www.investors.com/ibd-data-stories/avid-bioservices-joins-elite-club-of-stocks-with-rs-ratings-over-90/,2023-04-24 07:00:00,"On Monday, Avid Bioservices ( CDMO ) hit an important technical milestone, seeing its Relative Strength ( RS ) Rating jump into the 90-plus percentile with an improvement to 91, up from 87 the day before. When looking for the best stocks to buy and watch, one factor to watch closely is ...",TECH,0.306963,0.12624,Neutral
Recombinant proteins market is projected to grow at a CAGR of 11.14% by 2033: Visiongain Reports Ltd,https://www.benzinga.com/pressreleases/23/04/g31918969/recombinant-proteins-market-is-projected-to-grow-at-a-cagr-of-11-14-by-2033-visiongain-reports-ltd,2023-04-20 15:52:17,"Visiongain has published a new report: Recombinant Proteins Market:- Forecasts by Products & Services ( Cytokines & Growth Factors ( Interferons ( IFNs ) , Interleukins ( ILS ) , Others ) , Antibodies, Enzymes ( Kinases Enzymes, Metabolic Enzymes, Others ) , Recombinant Regulatory Protein, ...",TECH,0.029292,0.058959,Neutral
"Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors",https://www.globenewswire.com/news-release/2023/04/19/2649959/0/en/Keros-Therapeutics-Appoints-Alpna-Seth-Ph-D-to-its-Board-of-Directors.html,2023-04-19 12:00:00,"LEXINGTON, Mass., April 19, 2023 ( GLOBE NEWSWIRE ) -- Keros Therapeutics, Inc. ( ""Keros"" or the ""Company"" ) ( Nasdaq: KROS ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, ...",TECH,0.082393,-0.024434,Neutral
BIO-TECHNE AND LUNAPHORE ESTABLISH STRATEGIC PARTNERSHIP TO DEVELOP THE FIRST FULLY AUTOMATED SAME-SLIDE SPATIAL MULTIOMICS SOLUTION,https://www.prnewswire.com/news-releases/bio-techne-and-lunaphore-establish-strategic-partnership-to-develop-the-first-fully-automated-same-slide-spatial-multiomics-solution-301798423.html,2023-04-17 11:00:00,BIO-TECHNE AND LUNAPHORE ESTABLISH STRATEGIC ... PR ...,TECH,0.311829,0.255895,Somewhat-Bullish
"Bio-Techne  ( NASDAQ:TECH )  Upgraded to ""Buy"" by StockNews.com",https://www.defenseworld.net/2023/04/17/bio-techne-nasdaqtech-upgraded-to-buy-by-stocknews-com.html,2023-04-17 05:18:46,"Bio-Techne ( NASDAQ:TECH - Get Rating ) was upgraded by analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research note issued to investors on Monday.",TECH,0.863315,0.455863,Bullish
"Bio-Techne  ( NASDAQ:TECH )  Lowered to ""Hold"" at StockNews.com",https://www.defenseworld.net/2023/04/09/bio-techne-nasdaqtech-lowered-to-hold-at-stocknews-com.html,2023-04-09 05:14:45,"Bio-Techne ( NASDAQ:TECH - Get Rating ) was downgraded by StockNews.com from a ""buy"" rating to a ""hold"" rating in a research report issued on Sunday. Several other analysts have also issued reports on the stock.",TECH,0.865306,0.354346,Bullish
BIO-TECHNE COMPLETES INVESTMENT IN WILSON WOLF MANUFACTURING - Bio-Techne  ( NASDAQ:TECH ) ,https://www.benzinga.com/pressreleases/23/04/n31629205/bio-techne-completes-investment-in-wilson-wolf-manufacturing,2023-04-03 11:00:00,"MINNEAPOLIS, April 3, 2023 /PRNewswire/ -- Bio-Techne Corporation TECH today announced it has completed its investment in Wilson Wolf Manufacturing. Wilson Wolf achieved the trailing 12-month earnings before interest, taxes, depreciation, and amortization ( EBITDA ) target of $55 million, ...",TECH,0.802624,0.442832,Bullish
Bio-Techne  ( NASDAQ:TECH )  Lifted to Buy at StockNews.com,https://www.defenseworld.net/2023/04/01/bio-techne-nasdaqtech-lifted-to-buy-at-stocknews-com.html,2023-04-01 05:26:44,"Bio-Techne ( NASDAQ:TECH - Get Rating ) was upgraded by equities researchers at StockNews.com from a ""hold"" rating to a ""buy"" rating in a report released on Saturday.",TECH,0.898564,0.339826,Somewhat-Bullish
Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results,https://www.globenewswire.com/news-release/2023/03/30/2637497/0/en/Renalytix-Reports-Second-Quarter-and-First-Half-Fiscal-Year-2023-Financial-Results.html,2023-03-30 11:00:00,"LONDON and SALT LAKE CITY, March 30, 2023 ( GLOBE NEWSWIRE ) -- Renalytix plc ( NASDAQ: RNLX ) ( LSE: RENX ) , an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based ...",TECH,0.002444,0.062768,Neutral
Bio-Techne  ( NASDAQ:TECH )  Downgraded by StockNews.com to Hold,https://www.defenseworld.net/2023/03/25/bio-techne-nasdaqtech-downgraded-by-stocknews-com-to-hold.html,2023-03-25 09:34:45,StockNews.com downgraded shares of Bio-Techne ( NASDAQ:TECH - Get Rating ) from a buy rating to a hold rating in a report released on Friday morning. TECH has been the subject of a number of other reports. Robert W.,TECH,0.917988,0.4105,Bullish
"Increasing Investments and Fundings in Cell and Gene Therapy Fuelling the Growth of Cell and Gene Therapy Biomanufacturing, Suggests BIS Research Study",https://www.prnewswire.com/news-releases/increasing-investments-and-fundings-in-cell-and-gene-therapy-fuelling-the-growth-of-cell-and-gene-therapy-biomanufacturing-suggests-bis-research-study-301780593.html,2023-03-24 15:15:00,Increasing Investments and Fundings in Cell and Gene Therapy ... PR ...,TECH,0.088309,0.039338,Neutral
5 Best ETFs Tracking CRISPR Gene Editing,https://www.fool.com/investing/stock-market/market-sectors/healthcare/genomics-stocks/crispr-etfs/,2023-03-10 20:45:33,These exchange-traded funds track companies in this biotech space.,TECH,0.087503,0.057183,Neutral
Capillary electrophoresis market to grow CAGR of 5.7% from 2022 to 2027; Evolving opportunities with Agilent Technologies Inc and Bio Rad Laboratories Inc among others- Technavio,https://www.prnewswire.com/news-releases/capillary-electrophoresis-market-to-grow-cagr-of-5-7--from-2022-to-2027-evolving-opportunities-with-agilent-technologies-inc-and-bio-rad-laboratories-inc-among-others--technavio-301763247.html,2023-03-07 09:30:00,Capillary electrophoresis market to grow CAGR of 5.7% from 2022 ... PR ...,TECH,0.158519,0.0,Neutral
Bio-Techne  ( NASDAQ:TECH )  Stock Rating Upgraded by StockNews.com,https://www.defenseworld.net/2023/03/04/bio-techne-nasdaqtech-stock-rating-upgraded-by-stocknews-com.html,2023-03-04 08:56:42,Bio-Techne ( NASDAQ:TECH ) Stock Rating Upgraded by StockNews ... Defense World ...,TECH,0.867408,0.399535,Bullish
IVD Quality Control Market worth $1.6 Billion | MarketsandMarkets,https://www.prnewswire.com/news-releases/ivd-quality-control-market-worth-1-6-billion--marketsandmarkets-301749618.html,2023-02-17 18:30:00,"CHICAGO, Feb. 17, 2023 /PRNewswire/ -- The IVD quality control industry is expected to witness a significant growth in near future. This is due to the increasing demand for quality control in the health care sector and the development of new technologies and processes that can help improve ...",TECH,0.023464,0.072072,Neutral
5 Cheapest Health Care Stocks You Should Think About,https://www.benzinga.com/trading-ideas/long-ideas/23/01/30602080/5-cheapest-health-care-stocks-you-should-think-about,2023-01-27 13:48:05,"The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.",TECH,0.250386,0.265517,Somewhat-Bullish
"Bio-Techne  ( NASDAQ:TECH )  Lowered to ""Hold"" at StockNews.com",https://reporter.am/2023/01/26/bio-techne-nasdaqtech-lowered-to-hold-at-stocknews-com.html,2023-01-26 08:49:28,StockNews.com downgraded shares of Bio-Techne ( NASDAQ:TECH - Get Rating ) from a buy rating to a hold rating in a research note issued to investors on Thursday.,TECH,0.819893,0.431859,Bullish
"Bio-Techne  ( NASDAQ:TECH )  Lowered to ""Hold"" at StockNews.com",https://www.defenseworld.net/2023/01/26/bio-techne-nasdaqtech-lowered-to-hold-at-stocknews-com.html,2023-01-26 08:48:41,StockNews.com downgraded shares of Bio-Techne ( NASDAQ:TECH - Get Rating ) from a buy rating to a hold rating in a research note issued to investors on Thursday.,TECH,0.819893,0.431859,Bullish
Bio-Techne  ( NASDAQ:TECH )  Stock Rating Lowered by StockNews.com,https://www.etfdailynews.com/2023/01/26/bio-techne-nasdaqtech-stock-rating-lowered-by-stocknews-com/,2023-01-26 08:14:43,Bio-Techne ( NASDAQ:TECH ) Stock Rating Lowered by StockNews ... ETF Daily News ...,TECH,0.831429,0.418511,Bullish
Blotting Systems Market will worth USD 1.68 billion by 2030 : GreyViews,https://www.benzinga.com/pressreleases/23/01/g30550968/blotting-systems-market-will-worth-usd-1-68-billion-by-2030-greyviews,2023-01-24 16:00:00,"Pune India, Jan. 24, 2023 ( GLOBE NEWSWIRE ) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle East and Africa. These are the key regions where the blotting systems market is operating and is ...",TECH,0.023169,0.093513,Neutral
5 Health Care Stocks That Are Diving - And May Rally,https://www.benzinga.com/trading-ideas/long-ideas/23/01/30482724/5-health-care-stocks-that-are-diving-and-may-rally,2023-01-19 13:58:28,"The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.",TECH,0.234684,-0.233329,Somewhat-Bearish
"Bio-Techne  ( NASDAQ:TECH )  Upgraded to ""Buy"" by StockNews.com",https://reporter.am/2023/01/18/bio-techne-nasdaqtech-upgraded-to-buy-by-stocknews-com.html,2023-01-18 08:16:44,"Bio-Techne ( NASDAQ:TECH - Get Rating ) was upgraded by analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a note issued to investors on Wednesday.",TECH,0.855251,0.359636,Bullish
"Bio-Techne  ( NASDAQ:TECH )  Upgraded to ""Buy"" by StockNews.com",https://www.etfdailynews.com/2023/01/18/bio-techne-nasdaqtech-upgraded-to-buy-by-stocknews-com/,2023-01-18 08:16:44,"Bio-Techne ( NASDAQ:TECH - Get Rating ) was upgraded by investment analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research report issued on Wednesday. A number of other brokerages have also recently commented on TECH. Robert W.",TECH,0.825367,0.350989,Bullish
3 Trends We'll Tap For 7%+ Dividends And Upside In 2023,https://www.forbes.com/sites/michaelfoster/2023/01/14/3-trends-well-tap-for-7-dividends-and-upside-in-2023/,2023-01-14 14:58:00,"There are three big overlooked trends in the stock market now, and by tapping each one, we can set ourselves up for some very nice long-term gains in my favorite high-yield vehicles: closed-end funds (CEFs).",TECH,0.09439,0.059568,Neutral
Bio-Techne  ( NASDAQ:TECH )  Downgraded to Hold at StockNews.com,https://reporter.am/2023/01/11/bio-techne-nasdaqtech-downgraded-to-hold-at-stocknews-com.html,2023-01-11 08:48:44,StockNews.com cut shares of Bio-Techne ( NASDAQ:TECH - Get Rating ) from a buy rating to a hold rating in a research report released on Tuesday morning. Other equities research analysts have also recently issued research reports about the stock. Robert W.,TECH,0.75957,0.365602,Bullish
Should Vanguard SmallCap Growth ETF  ( VBK )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2036572/should-vanguard-smallcap-growth-etf-vbk-be-on-your-investing-radar,2023-01-09 11:20:07,Style Box ETF report for ...,TECH,0.124164,0.081451,Neutral
ELISpot and FluoroSpot Assay Market worth $390 million by 2027 - Exclusive Report by MarketsandMarkets™,https://www.benzinga.com/pressreleases/23/01/g30325706/elispot-and-fluorospot-assay-market-worth-390-million-by-2027-exclusive-report-by-marketsandmarket,2023-01-09 08:00:00,"Chicago, Jan. 09, 2023 ( GLOBE NEWSWIRE ) -- According to the new market research report ""ELISpot and FluoroSpot Assay Market by Product ( Assay Kit ( T Cell and B Cell assay ) , Analyzer, Ancillary Products ) , Application ( Transplants, Vaccine Development ) , End User ( Hospitals & Clinical ...",TECH,0.073546,-0.028175,Neutral
"StockNews.com Upgrades Bio-Techne  ( NASDAQ:TECH )  to ""Buy""",https://www.etfdailynews.com/2023/01/03/stocknews-com-upgrades-bio-techne-nasdaqtech-to-buy/,2023-01-03 07:16:42,StockNews.com upgraded shares of Bio-Techne ( NASDAQ:TECH - Get Rating ) from a hold rating to a buy rating in a research report report published on Monday. TECH has been the subject of several other reports.,TECH,0.867268,0.382206,Bullish
"Bio-Techne  ( NASDAQ:TECH )  Upgraded to ""Buy"" at StockNews.com",https://reporter.am/2023/01/03/bio-techne-nasdaqtech-upgraded-to-buy-at-stocknews-com.html,2023-01-03 07:16:42,StockNews.com upgraded shares of Bio-Techne ( NASDAQ:TECH - Get Rating ) from a hold rating to a buy rating in a research report report published on Monday morning. Several other analysts have also recently weighed in on the stock.,TECH,0.799771,0.37206,Bullish
